SusanneMarkesberyArnoldMD

Clinical Trials

• Phase I Trial of Biweekly Gemcitabine & Paclitaxel & Low-Dose Radiation for Metastatic or Recurrent Head & Neck Cancer Start of enrollment: 2005 Dec 01

  Terminated

  Phase 1

• Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer Start of enrollment: 2000 May 01

  Completed

  Phase 2

• Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer Start of enrollment: 2002 Sep 01

  Completed

  Phase 2

• S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Start of enrollment: 2006 May 01

  Completed

  Phase 2

• Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent NSCLC Start of enrollment: 2004 Nov 01

  Terminated

  Phase 1

• Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies Start of enrollment: 2006 Oct 01

  Completed

  Phase 1

• Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08

  Active, not recruiting

  Phase 3

• Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15

  Completed

  Phase 3

• Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma Start of enrollment: 2010 Mar 15

  Active, not recruiting

  Phase 1, Phase 2

• Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma Start of enrollment: 2009 Dec 01

  Unknown status

  Phase 2

• A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies Start of enrollment: 2010 Sep 01

  Completed

  Phase 1

• Study of Lung Cancer in Appalachian Kentucky: The Role of Environmental Carcinogens Start of enrollment: 2011 Sep 01

  Completed

• Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients Start of enrollment: 2013 Nov 01

  Completed

  Phase 1, Phase 2

• A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN Start of enrollment: 2014 Oct 01

  Completed

  Phase 2

• Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08

  Completed

• Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Start of enrollment: 2015 Jun 26

  Completed

  Phase 1, Phase 2

• Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Start of enrollment: 2016 Jan 25

  Completed

  Phase 2

• Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01

  Completed

  Phase 2

• Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01

  Completed

  Phase 2, Phase 3

• Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29

  Active, not recruiting

  Phase 3

• Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer Start of enrollment: 2022 Jul 25

  Recruiting

  Phase 2

  Roles: Principal Investigator, Contact

• Join now to see all